354 related articles for article (PubMed ID: 26019189)
21. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
23. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
24. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
[TBL] [Abstract][Full Text] [Related]
25. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
[TBL] [Abstract][Full Text] [Related]
26. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges.
See SHC; Siziopikou KP
Pathol Res Pract; 2022 Feb; 230():153753. PubMed ID: 34990870
[TBL] [Abstract][Full Text] [Related]
27. Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.
Wang S; Zhang Y; Yang X; Fan L; Qi X; Chen Q; Jiang J
World J Surg Oncol; 2013 Jul; 11(1):166. PubMed ID: 23883300
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.
Mayer EL; Carey LA; Burstein HJ
Breast Cancer Res; 2007; 9(5):110. PubMed ID: 17888189
[TBL] [Abstract][Full Text] [Related]
29. Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy.
Fontanella C; Loibl S; von Minckwitz G
Breast; 2015 Nov; 24 Suppl 2():S84-7. PubMed ID: 26279131
[TBL] [Abstract][Full Text] [Related]
30. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
[TBL] [Abstract][Full Text] [Related]
31. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
32. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
33. Treatment of residual disease following neoadjuvant therapy in breast cancer.
Heater NK; Somayaji K; Gradishar W
J Surg Oncol; 2024 Jan; 129(1):18-25. PubMed ID: 37990834
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age.
Provenzano E
Acta Med Acad; 2021 Apr; 50(1):88-109. PubMed ID: 34075766
[TBL] [Abstract][Full Text] [Related]
35. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Symmans WF; Peintinger F; Hatzis C; Rajan R; Kuerer H; Valero V; Assad L; Poniecka A; Hennessy B; Green M; Buzdar AU; Singletary SE; Hortobagyi GN; Pusztai L
J Clin Oncol; 2007 Oct; 25(28):4414-22. PubMed ID: 17785706
[TBL] [Abstract][Full Text] [Related]
36. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
[TBL] [Abstract][Full Text] [Related]
37. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.
Reinisch M; Huober J; von Minckwitz G; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Schneeweiss A; Rhiem K; Lederer B; Untch M; Nekljudova V V; Loibl S
Breast; 2017 Apr; 32():73-78. PubMed ID: 28063331
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
[TBL] [Abstract][Full Text] [Related]
39. Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response.
Santamaría G; Bargalló X; Ganau S; Alonso I; Muñoz M; Mollà M; Fernández PL; Prat A
Eur J Radiol; 2019 Aug; 117():132-139. PubMed ID: 31307638
[TBL] [Abstract][Full Text] [Related]
40. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
